Search

MSK medical oncologist Shanu Modi is the lead author of a new paper detailing the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. Results from this study were also presented at the San Antonio Breast Cancer Symposium.

… Wednesday, December 11, 2019 Summary A new study in the New England Journal of Medicine details the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. MSK medical oncologist Shanu Modi is the lead author of the paper, which was also presented at the San Antonio

Researchers have discovered a simple way to keep stem cells in a more flexible state for research and potential treatments.

… Thursday, June 27, 2019 Summary Stem cells that are pluripotent can develop into any cell type. These stem cells are easier to work with in their earlier naive state of pluripotency. Researchers have discovered that a commonly used fat-free culture medium can shift human stem cells closer to this naive

Up to 20 percent of people over the age of 70 have clonal hematopoiesis of indeterminate potential (CHIP), a condition that carries twice the risk of coronary heart disease and ischemic stroke, and worse outcomes after heart failure — independent of traditional cardiovascular risk factors.

… Tuesday, October 8, 2019 Up to 20 percent of people over the age of 70 have clonal hematopoiesis of indeterminate potential (CHIP), a condition that carries twice the risk of coronary heart disease and ischemic stroke, and worse outcomes after heart failure — independent of traditional cardiovascular

在 70 岁以上的人群中，高达 20% 的人有不确定潜能的克隆性造血 (CHIP)，这种情况会带来双倍冠心病和缺血性中风风险，并且导致心力衰竭后预后更差 — 无论传统的心血管风险因素如何。

… Tuesday, October 8, 2019 在 70 岁以上的人群中，高达 20% 的人有不确定潜能的克隆性造血 (CHIP)，这种情况会带来双倍冠心病和缺血性中风风险，并且导致心力衰竭后预后更差 — 无论传统的心血管风险因素如何。 该状况包括由造血干细胞中的体细胞突变引起的外周血突变白细胞。随着人口老龄化的增长，越来越多 CHIP 患者将前往心血管医生处就诊。 就使用 CHIP 筛查、评估和管理患者的最佳方法，仍存在一些疑问。我们和其他癌症研究中心的同事们一起，最近在 《美国心脏病学会杂志》 上发表了一篇论文。我们在论文中对 CHIP 进行了说明，回顾了一些临床问题，为 CHIP 患者的心血管风险管理提供了一些合理化建议

Help save lives. Get immunized.

… Friday, December 18, 2020 Memorial Sloan Kettering (MSK) Healthcare Heroes are rolling up their sleeves to receive the COVID-19 vaccine. COVID-19 vaccination is our best shot at controlling/ ending this global pandemic and helping protect our immunocompromised patients, their families, MSK staff, and

Researchers at the Sloan Kettering Institute have found that gut microbes shape the immune system of mice in an unexpected way.

… Wednesday, May 12, 2021 The immune system’s main job is identifying things that can make us sick. In the language of immunology, this means distinguishing “self” from “non-self”: The cells of our organs are self, while disease-causing bacteria and viruses are non-self. But what about the billions of

Read about a new treatment combining bispecific antibodies that is effective against extramedullary myeloma.

… Sunday, December 7, 2025 Researchers have made  great progress in the treatment of  multiple myeloma , a rare blood cancer, over the past decade. One important advance has been the emergence of a new class of drugs called bispecific antibodies, which work well in people for whom previous treatments have

A new finding provides insight into how breast cancer develops resistance to aromatase inhibitors.

… Thursday, September 3, 2020 Summary Many patients with estrogen-positive breast cancer develop resistance to drugs called aromatase inhibitors. MSK researchers have discovered that mutations in a gene called FOXA1 cause the cancer cells to grow and resist aromatase inhibitors in distinct ways. Most breast

Lung resection after initial nonoperative treatment for non-small cell lung cancer (NSCLC) was safe and led to significantly improved survival in select patients previously treated with nonoperative therapies, according to a study by Memorial Sloan Kettering Cancer Center (MSK) investigators.

… Monday, March 18, 2024 Lung resection after initial nonoperative treatment for non-small cell lung cancer (NSCLC) was safe and led to significantly improved survival in select patients previously treated with nonoperative therapies, according to a study by Memorial Sloan Kettering Cancer Center (MSK)

Memorial Sloan Kettering Cancer Center (MSK) is committed not only to providing exceptional cancer care but also to ensuring access to care for everyone who needs it. Unfortunately, some patients — often those whose insurance plan offers a very narrow provider network or those who are underinsured — have trouble shouldering the significant financial burden that can come with a cancer diagnosis. MSK has a special team in place to make sure these patients can still get the care they deserve.

… Monday, February 27, 2023 Memorial Sloan Kettering Cancer Center (MSK) is committed not only to providing exceptional cancer care but also to ensuring access to care for everyone who needs it. Unfortunately, some patients — often those whose insurance plan offers a very narrow provider network or those